Abstract
The constant exposure of implantable biomaterials such as titanium and titanium alloys to blood-introducesserious and ongoing concerns regarding poor blood-material interactions. To date, all blood-contacting materials have been shown to initiate immunological events in the form of inflammation, thrombosis, fibrosis and infection; potentially leading to complete implant failure. Material surfaces that provide biomimetic cues such as nanoscale architectures have been shown to elicit improved cellular interaction; and thus, may provide possible solutions for enhancing bloodcompatibility. However, limited information exists about the thrombogenicityof nanoscalesurface architectures. In this study, we have evaluated the efficacy of titania nanotube arrays as interfaces for blood contacting devices by investigating the thrombogenic effects using whole blood plasma. Thus, platelet/leukocyte adhesion, activation and interaction, morphology, complement activation, contact activation, platelet release reaction, fibrinogen expression and material cytotoxicity were evaluated to determine the in vitro thrombogenicity. The results presented here indicate a decrease in thrombogenic effects oftitania nanotube arrays as compared to biomedical grade titanium after 2 hours of contact with whole blood plasma. This work shows the improved blood-compatibility of titania nanotube arrays, identifying this specific nanoarchitecture as a potentially optimal interface for promoting the long-term success of blood contacting biomaterials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 642-658 |
| Number of pages | 17 |
| Journal | Journal of Biomedical Nanotechnology |
| Volume | 8 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2012 |
| Externally published | Yes |
Fingerprint
Keywords
- Leukocytes
- Platelets
- Thrombogenicity
- Titania nanotube arrays
- Whole blood plasma
ASJC Scopus subject areas
- Materials Science(all)
- Bioengineering
- Biomedical Engineering
- Medicine (miscellaneous)
- Pharmaceutical Science
Cite this
Titania nanotube arrays as interfaces for blood-contacting implantable devices : A study evaluating the nanotopography-associated activation and expression of blood plasma components. / Smith, Barbara; Popat, Ketul C.
In: Journal of Biomedical Nanotechnology, Vol. 8, No. 4, 08.2012, p. 642-658.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Titania nanotube arrays as interfaces for blood-contacting implantable devices
T2 - A study evaluating the nanotopography-associated activation and expression of blood plasma components
AU - Smith, Barbara
AU - Popat, Ketul C.
PY - 2012/8
Y1 - 2012/8
N2 - The constant exposure of implantable biomaterials such as titanium and titanium alloys to blood-introducesserious and ongoing concerns regarding poor blood-material interactions. To date, all blood-contacting materials have been shown to initiate immunological events in the form of inflammation, thrombosis, fibrosis and infection; potentially leading to complete implant failure. Material surfaces that provide biomimetic cues such as nanoscale architectures have been shown to elicit improved cellular interaction; and thus, may provide possible solutions for enhancing bloodcompatibility. However, limited information exists about the thrombogenicityof nanoscalesurface architectures. In this study, we have evaluated the efficacy of titania nanotube arrays as interfaces for blood contacting devices by investigating the thrombogenic effects using whole blood plasma. Thus, platelet/leukocyte adhesion, activation and interaction, morphology, complement activation, contact activation, platelet release reaction, fibrinogen expression and material cytotoxicity were evaluated to determine the in vitro thrombogenicity. The results presented here indicate a decrease in thrombogenic effects oftitania nanotube arrays as compared to biomedical grade titanium after 2 hours of contact with whole blood plasma. This work shows the improved blood-compatibility of titania nanotube arrays, identifying this specific nanoarchitecture as a potentially optimal interface for promoting the long-term success of blood contacting biomaterials.
AB - The constant exposure of implantable biomaterials such as titanium and titanium alloys to blood-introducesserious and ongoing concerns regarding poor blood-material interactions. To date, all blood-contacting materials have been shown to initiate immunological events in the form of inflammation, thrombosis, fibrosis and infection; potentially leading to complete implant failure. Material surfaces that provide biomimetic cues such as nanoscale architectures have been shown to elicit improved cellular interaction; and thus, may provide possible solutions for enhancing bloodcompatibility. However, limited information exists about the thrombogenicityof nanoscalesurface architectures. In this study, we have evaluated the efficacy of titania nanotube arrays as interfaces for blood contacting devices by investigating the thrombogenic effects using whole blood plasma. Thus, platelet/leukocyte adhesion, activation and interaction, morphology, complement activation, contact activation, platelet release reaction, fibrinogen expression and material cytotoxicity were evaluated to determine the in vitro thrombogenicity. The results presented here indicate a decrease in thrombogenic effects oftitania nanotube arrays as compared to biomedical grade titanium after 2 hours of contact with whole blood plasma. This work shows the improved blood-compatibility of titania nanotube arrays, identifying this specific nanoarchitecture as a potentially optimal interface for promoting the long-term success of blood contacting biomaterials.
KW - Leukocytes
KW - Platelets
KW - Thrombogenicity
KW - Titania nanotube arrays
KW - Whole blood plasma
UR - http://www.scopus.com/inward/record.url?scp=84865122084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865122084&partnerID=8YFLogxK
U2 - 10.1166/jbn.2012.1421
DO - 10.1166/jbn.2012.1421
M3 - Article
C2 - 22852474
AN - SCOPUS:84865122084
VL - 8
SP - 642
EP - 658
JO - Journal of Biomedical Nanotechnology
JF - Journal of Biomedical Nanotechnology
SN - 1550-7033
IS - 4
ER -